Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hong, Jing ^a   Wang, Hang ^a   Shen, Guoying ^a   Lin, Da ^a   Lin, Yanxue ^a   Guo, Yashan ^a   Li, Qiaoling ^a   Ye, Nanhui ^a   Deng, Chengjun ^a   Meng, Chun ^a  

^a FUZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; RECOMBINANT PROTEIN;

ANIMAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964318875     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24397     Document Type: Article

References (42)

1. Forman, D., Ferlay, J. In World cancer report, (eds Stewart, B. W., Wild, C. P.) 1-5 (International Agency for Research on Cancer, 2014).
2. Hytiroglou, P., Park, Y. N., Krinsky, G., Theise, N. D. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterology clin. North Am. 36, 867-887, vii (2007).
3. Liu, H. et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis 36, 459-468 (2015).
4. Liu, Y., Fuchs, J., Li, C., Lin, J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell cycle 9, 3423-3427 (2010).
5. Liu, Y., Li, P. K., Li, C., Lin, J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 285, 27429-27439 (2010).
6. Otsuki, T. et al. IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor. Int. J. oncol. 23, 763-768 (2003).
7. Piccioni, F. et al. 4-Methylumbelliferone inhibits hepatocellular carcinoma growths by decreasing IL-6 production and angiogenesis. Glycobiology 25, 825-835 (2015).
8. Poma, P. et al. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int. J. Oncol. 28, 923-930 (2006).
9. He, G. et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155, 384-396 (2013).
10. Yao, X. et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmaco. Ther. 141, 125-139 (2014).
11. Hatting, M. et al. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Cell Death Dis. 6, e1667 (2015).
12. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitisassociated tumorigenesis. Cancer cell 15, 91-102 (2009).
13. Hausherr, A. et al. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene 26, 4987-4998 (2007).
14. Goumas, F. A. et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. International journal of cancer. Int. J. Cancer 137, 1035-1046 (2015).
15. Johnson, C. et al. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl. Gastrointestinal Cancer 1, 58-70 (2012).
16. Kao, J. T. et al. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterology 15, 50 (2015).
17. Ho, M. C. et al. Using ultrasound Nakagami imaging to assess liver fibrosis in rats. Ultrasonics 52, 215-222 (2012).
18. Nakayama, Y. et al. Ultrastructural localization of type IV collagen and laminin in the Disse space of rat liver with carbon tetrachloride induced fibrosis. Liver 11, 260-271 (1991).
19. Ala-Kokko, L., Gunzler, V., Hoek, J. B., Rubin, E., Prockop, D. J. Hepatic fibrosis in rats produced by carbon tetrachloride and dimethylnitrosamine: observations suggesting immunoassays of serum for the 7S fragment of type IV collagen are a more sensitive index of liver damage than immunoassays for the NH2-terminal propeptide of type III procollagen. Hepatology 16, 167-172 (1992).
20. Tamaro, G., Danek, G. M., Mangiarotti, M. A., Tamaro, P., Zanazzo, G. A. Methotrexate therapy and liver fibrosis: are human prolyl hydroxylase and type IV collagen reliable and sensitive markers? Int. J. Clin. Lab. Res. 25, 55 (1995).
21. Mak, K. M., Chen, L. L., Lee, T. F. Codistribution of collagen type IV and laminin in liver fibrosis of elderly cadavers: immunohistochemical marker of perisinusoidal basement membrane formation. Anat. Rec. (hoboken) 296, 953-964 (2013).
22. Aida, Y. et al. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease. J. Gastrointestin. Liver Dis. 24, 61-68 (2015).
23. Tseng, P. L. et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J. Surg. Oncol. 98, 349-357 (2008).
24. Scartozzi, M. et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int. J. Cancer 135, 1247-1256 (2014).
25. Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160-167 (2001).
26. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588 (2000).
27. Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13, 139-145 (2007).
28. Spaccarotella, E. et al. STAT3-mediated activation of microRNA cluster 17 ~ 92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica 99, 116-124 (2014).
29. Coussens, L. M., Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
30. Balkwill, F., Charles, K. A., Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer cell 7, 211-217 (2005).
31. Lin, W. W., Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175-1183 (2007).
32. Hsiao, Y. W. et al. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol. Immunother. 57, 1091-1104 (2008).
33. Tang, Y. et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. USA 105, 2445-2450 (2008).
34. Wang, X., Sun, J. Study on the correlation between EGFR-STAT3 signal pathway and laryngeal papilloma. J. Clin. Otorhinolaryngolog Head Neck Surg. 23, 832-836 (2009).
35. Garbers, C., Aparicio-Siegmund, S., Rose-John, S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin. Immunol. 34C, 75-82 (2015).
36. Preobrazhensky, S., Malugin, A., Wentz, M. Flow cytometric assay for evaluation of the effects of cell density on cytotoxicity and induction of apoptosis. Cytometry 43, 199-203 (2001).
37. Chen, Z. et al. Induction of apoptosis and suppression of clonogenicity of ovarian carcinoma cells with estrogen mustard. Cancer 85, 2616-2622 (1999).
38. Furuhata, A. et al. Rapid multiple immunocytochemical staining method using microwave irradiation for intraoperative cytology. Acta cytol. 54, 283-290 (2010).
39. Kadar, A., Wittmann, G., Liposits, Z., Fekete, C. Improved method for combination of immunocytochemistry and Nissl staining. J. Neurosci. Methods 184, 115-118 (2009).
40. Singh, R., Sharma, J., Goyal, P. K. Prophylactic Role of Averrhoa carambola (Star Fruit) Extract against Chemically Induced Hepatocellular Carcinoma in Swiss Albino Mice. Adv. Pharmacol. Sci. 2014, 158936 (2014).
41. Roato, I. et al. Bone invading NSCLC cells produce IL-7: mice model and human histologic data. BMC cancer 10, 12 (2010).
42. Qiu, W. et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis 4, e599 (2013).